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ORIGINAL ARTICLE
Genetic Association Analysis Reveals Differences in the
Contribution of NOD2 Variants to the Clinical Phenotypes of
Orofacial Granulomatosis
Alexander Mentzer, MBBS, MRCP,* Shalini Nayee, BDS,† Yasmin Omar, MRes,† Esther Hullah, MBBS,‡
Kirstin Taylor, MBBS,† Rishi Goel, MBBS,‡ Hannah Bye, PhD,† Tarik Shembesh, BDS, RCS,‡
Timothy R. Elliott, PhD,* Helen Campbell, PhD,§ Pritash Patel, MD, MRCP,* Anita Nolan, MD, FFDRCSI,k
John Mansﬁeld, MD, FRCP,¶ Stephen Challacombe, PhD, FDSRCS,‡ Michael Escudier, MD, FDSRCS,‡
Christopher G. Mathew, PhD,†,** Jeremy D. Sanderson, MD, FRCP,* and Natalie J. Prescott, PhD†
Background: Orofacial granulomatosis (OFG) is a rare, inﬂammatory disorder of the mouth, in which some patients also have intestinal Crohn’s
disease (CD). The etiology remains largely unknown, although there is a high prevalence of atopy, and oral granulomas are also seen in other immune
disorders particularly CD and sarcoidosis. We investigated whether genetic variants associated with an increased risk of CD, sarcoidosis, or atopy were
also associated with susceptibility to OFG.
Methods: Patients were stratiﬁed clinically as isolated oral manifestations (OFG only) or concurrent intestinal CD (OFG+CD). We genotyped 201
patients and 1023 healthy controls for risk variants in NOD2, IRGM, IL23R, ATG16L1 (CD), BTNL2 (sarcoidosis), and FLG (atopy). The coding regions
of the NOD2 gene were screened for rare, potentially pathogenic variants in OFG.
Results: A combined analysis of 3 CD-risk variants in NOD2 showed no association with any OFG subgroup. NOD2 p.L1007insC was associated with OFG
+CD (P ¼ 0.023) and IL23R p.R381Q with all OFG (P ¼ 0.031). The sarcoidosis risk variant rs2076530 in BTNL2 was associated with all OFG (P ¼ 0.013).
We identiﬁed 7 rare missense NOD2 alleles in 8 individuals with OFG, 4 OFG-only patients and 4 patients with OFG+CD. There was a signiﬁcant enrichment
of NOD2 variants in the OFG+CD group compared to the OFG-only group (P ¼ 0.008, common variants; P ¼ 0.04, all common and rare variants).
Conclusions: Our ﬁndings suggest that genetic variants in NOD2 are only associated with OFG in patients with concurrent intestinal disease. A
genome-wide association scan is needed to fully deﬁne the genetic architecture of OFG.
(Inﬂamm Bowel Dis 2016;22:1552–1558)
Key Words: orofacial granulomatosis, Crohn’s disease, NOD2 gene, genetic association
O rofacial granulomatosis (OFG) is a chronic inﬂammatory dis-order affecting the mouth and perioral region, typically pre-
senting with swelling of the lips and inﬂammation of the gingivae,
buccal mucosa, ﬂoor of mouth, and other sites within the oral
cavity.1 The precise incidence and prevalence of OFG are unknown,
although it is rarely seen in general medical or dental practice and is
managed by hospital specialists in secondary and tertiary care en-
vironments. Guy’s Hospital in London is a specialist center for
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OFG and has provided care for more than 250 patients from
throughout the United Kingdom.
The term OFG has been used classically to describe oral
pathology in the absence of any other systemic illness, but the
disease may occur in a manner clinically and histologically
indistinguishable from Crohn’s disease (CD) of the mouth.
Indeed, some centers now classify the disease into 3 categories:
OFG alone, OFG with intestinal CD, and OFG with gastrointes-
tinal granulomata but no symptoms of intestinal CD.2,3 Approxi-
mately 10% of adult and 20% of child patients may progress from
having OFG alone to the development of intestinal CD and pa-
tients with CD may also develop OFG, but it is very difﬁcult to
predict the course of disease in any particular patient.4
Other ﬁndings also present compelling reasons to question
whether OFG is simply a localized disorder.2,5 Ileocolonoscopy
performed on 35 OFG-only individuals revealed that 19 had
asymptomatic macroscopic and microscopic intestinal abnormal-
ities.2 This raises the possibility that OFG is a manifestation of an
alternate form of CD, with an attenuated intestinal phenotype but
a more severe oral phenotype. However, intestinal biopsies from
these 19 patients also showed histological features that differ from
the characteristic features of CD, leading to the proposal that OFG
could represent a novel form of inﬂammatory bowel disease.2 A
recent study examining the clinical characteristics of 21 OFG
patients with concomitant CD from Sweden showed that, when
compared with those with CD alone, this group represented a dis-
tinctive subphenotype of CD, particularly with respect to
increased perianal disease, ileocolonic inﬂammation, and intesti-
nal granulomata.6
The etiology of OFG is unknown. There has been no formal
study investigating the heritability of OFG, and it does not seem to
segregate in a Mendelian manner. Although it is now assumed that
OFG is a complex trait, there have been few attempts to identify
genetic susceptibility variants. It has been suggested that certain
HLA serotypes may have a role in the etiology of OFG,7 but these
ﬁndings have not been replicated to date. Unlike OFG, the genetic
contribution to CD pathogenesis has been much more widely inves-
tigated. The ﬁrst and most extensively replicated genetic ﬁndings in
CD have been the association of 3 loss-of-function variants in
NOD2 (nucleotide oligomerisation domain containing gene 2; p.
R702W, p.G908R, and p.L1007insC), a gene important in mediat-
ing the early antimicrobial response.8–11 Cumulatively, these var-
iants represent the strongest genetic risk factors identiﬁed for CD,12
and the many genome-wide association studies performed to date
have yet to ﬁnd a locus with a higher attributable risk. Further DNA
sequencing studies have identiﬁed another 6 missense and presum-
ably loss-of-function variants in NOD2 that are also signiﬁcantly
associated with increased CD risk,13,14 increasing the count of
known causal variants in this gene to at least 9.
The close clinical association between CD and OFG suggests
that they may have a similar genetic predisposition. Interestingly,
a recent study of 29 OFG cases in Sweden investigated the role of
the 3 major known CD-risk variants in NOD2 by analysis of each
variant (p.R702W, p.G908R, and p.L1007insC). They found that 4
of 12 OFG patients with concurrent CD carried one of these var-
iants, whereas none of the 17 OFG patients without concurrent CD
carried any risk variant, suggesting that these 2 groups of patients
might be genetically distinct.15 However, the more recently discov-
ered CD-associated NOD2 variants (p.M863V, p.D825S, p.R703C,
p.S431L, p.V793M, and p.R311W) were not considered in this
study; neither was the possible contribution of the novel variants
in NOD2. The authors emphasized that these ﬁndings needed to be
conﬁrmed in a larger cohort of well-deﬁned patients.
Genome-wide studies have been very successful in
revealing new important molecular pathways thought to con-
tribute to the pathogenesis of CD. The association of SNPs at the
interleukin-23 receptor gene (IL23R) locus with CD16 ﬁts with
the emerging major role of IL-23 and Th17 cells in mucosal
inﬂammation.17 In addition, associations of coding or regulatory
variants within ATG16L118,19 and IRGM20,21 identiﬁed the link
between CD and bacterial clearance.22,23 A recent meta-analysis
of genome-wide association studies on CD by the International
IBD Genetics Consortium, followed by extensive conﬁrmation
of association signals in more than 75,000 individuals has
increased the number of CD-associated loci to 14024 and
observed that many of these loci are also implicated in other
immune-mediated disorders.
In addition to the overlap in clinical phenotype between
OFG and CD, oral granulomata may also be found in a variety of
other disorders, including Mycobacterium tuberculosis infection,
Melkersson–Rosenthal syndrome, cheilitis granulomatosa, and
sarcoidosis. Sarcoidosis is a complex multisystemic immune dis-
order with a reported genetic etiology25 that predominantly affects
not only the lung but also the face and skin. One of the most well-
replicated genetic associations in adult sarcoidosis involves an
exonic splice site variant in exon 5 of the BTNL2 (butyrophilin-
like protein 2) gene, which results in loss of function due to
truncation of the protein product,26,27 although the association
may reﬂect linkage disequilibrium with the nearby HLA-DRB1.28
Butyrophilins are implicated in T-cell inhibition and the modulation
of epithelial cell–T-cell interactions,29 and we have shown recently
that a rare variant in BTNL2 is associated with inﬂammatory bowel
disease.30
A further component of the pathogenesis of OFG is the
increased prevalence of allergy with a high incidence of
concurrent hay fever, asthma, atopic dermatitis, elevated serum
immunoglobulin E (Ig E), and dietary allergies.4,31,32 This sug-
gests that OFG has an allergy-mediated pathogenesis, perhaps as
a delayed hypersensitivity reaction.31 This possibility is supported
further by the discovery of a novel class of dendritic B lympho-
cytes that preferentially express IgE in OFG biopsy specimens.33
One form of atopy that has been demonstrated to have a strong
genetic predisposition is atopic dermatitis. Loss-of-function mu-
tations in the FLG (ﬁlaggrin) gene, including p.R501X and
c.2282del4, are important risk factors in the etiology of sporadic
and familial forms of atopic dermatitis and asthma.34,35 Filaggrin
is a ﬁlament-aggregating protein, important in the formation of the
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corniﬁed cell envelope and has a key role in maintaining barrier
function.
The histological similarity between the granulomatous
lesions in OFG, CD, and sarcoidosis, the close clinical
association between OFG and CD, and the frequent association
with atopy seen in OFG led us to the hypothesis that these
disorders may have genetic risk factors in common. We
therefore tested genetic variants known to be strongly associated
with an increased risk of CD (NOD2, IRGM, IL23R, and
ATG16L1), sarcoidosis (BTNL2), and atopy (FLG) for associa-
tion with OFG. Also, in view of the known contribution of rare
genetic variants in the NOD2 gene to the development of CD, we
screened all coding regions of NOD2 for additional rare, known,
or novel genetic variants in OFG or the combined phenotype of
CD and OFG (CD+OFG).
METHODS
Patient Selection and
Phenotype Determination
Two hundred one patients with a diagnosis of OFG with and
without symptoms of intestinal CD were recruited into the study
from joint oral medicine/gastroenterology clinics at Guy’s and
St. Thomas Hospitals, London, and The Newcastle upon Tyne
Hospitals after informed consent in accordance with the local ethics
committees (REC Number: 12/YH/0172). Oral medicine specialists
and gastroenterologists experienced in the management of OFG
and CD classiﬁed each patient into one of 2 phenotypic categories
based on clinical features and speciﬁc investigations. The pheno-
typic categories included OFG only (OFG without any intestinal
symptoms, n ¼ 111) and OFG+CD (oral manifestations consistent
with a diagnosis of OFG with endoscopic and/or radiological evi-
dence of intestinal CD, n ¼ 90). The presence of microscopic
granulomata alone in otherwise normal intestinal mucosa, with
no intestinal symptoms, was considered insufﬁcient for a classiﬁca-
tion of OFG+CD in this study. DNA from 1023 population controls
was obtained from the 1958 British Birth Cohort, which includes
subjects born in 1 week of March 1958 in England, Scotland, and
Wales as previously described.36
Genetic Analysis
Genomic DNA was extracted from 10 mL of whole blood and
genotyped for risk variants strongly associated with CD (rs2066847/
NOD2 p.Leu1007fs, rs2066845/NOD2 p.G908R, rs2066844/NOD2
p.R702W, rs11209026/IL23R p.R381Q, rs13361189/IRGM upstream,
and rs2241880/ATG16L1 p.T300A), sarcoidosis (rs2076530/BTNL2
c.1078A.G), or atopic dermatitis (FLG p.R501X and c.2282del4)
using Applied Biosystems TaqMan assays (Life Technologies). All
variants tested were in Hardy–Weinberg equilibrium in cases and
controls (Hardy–Weinberg equilibrium P . 0.05) and had a greater
than 95% genotype pass rate for each variant.
The 12 exons of NOD2 were ampliﬁed by PCR in 17
amplicons as described previously37 in 201 patients with OFG.
These were then subjected to Sanger sequencing using a ABI Big
Dye v3.0 and ABI 3730XL DNA analyzer.
Statistical Analysis
Single-marker allele frequencies in the risk genes of interest
were compared using x2 statistics on SNPs with a minor allele
frequency of .1% and with Hardy–Weinberg equilibrium
P . 0.05. Genes containing multiple coding variants (NOD2
and FLG) were analyzed in a composite (gene-burden) manner
to assess whether the total number of risk alleles for that gene was
higher in cases compared with controls. All comparisons were
performed for all OFG cases (n ¼ 201) and the 2 subphenotypes
of OFG only (n ¼ 111) and OFG+CD (n ¼ 90). All P values and
odds ratios (ORs) were calculated using the R program (http://
www.r-project.org/). Based on published ORs for each disease-
speciﬁc variant, we had .99% power to detect an association at
NOD2 (for the 3 CD variants combined), 98% for BTNL2, 86%
for IL23R, and 78% for FLG 2282del. The power to detect asso-
ciation at the remaining loci is shown in Table, Supplemental
Digital Content 1, http://links.lww.com/IBD/B286, which con-
tains the results of all power calculations for all tested loci.
Pathogenicity Prediction
A combination of 9 online pathogenicity prediction soft-
ware programs were used (SIFT, PROVEAN, PANTHER,
PhD-SNP, SNAP, MetaSNP, MAPP, PolyPhen1, and PolyPhen2)
to predict the potential impact of each NOD2 missense variant on
gene function. These were run either independently or in parallel
by means of the online consensus SNP/variant analyzer tools
MetaSNP (http://snps.biofold.org/meta-snp/) and PredictSNP
(http://loschmidt.chemi.muni.cz/predictsnp/). Variants were con-
sidered pathogenic if the overall consensus of both Meta-SNP
and PredictSNP was “Disease”/“Deleterious.”38,39
RESULTS
DNA samples from 201 patients (111 OFG only and 90 OFG
+CD) were genotyped for variants known to be strongly associated
with an increased risk of CD (NOD2, IRGM, IL23R, and
ATG16L1), sarcoidosis (BTNL2), and atopy (FLG). A comparison
of the case–control allele frequencies for each SNP is provided in
Table 1. We observed suggestive association of the CD-risk alleles
at NOD2 p.L1007insC and IL23R p.R381Q with OFG in the pres-
ence of concurrent CD (OFG+CD; P ¼ 0.023 and P ¼ 0.038,
respectively). In addition, we observed association of the IL23R
p.R381Q risk variant when all 201 OFG cases were considered
regardless of intestinal phenotype (P ¼ 0.031), but no association
was detected for the OFG-only group (P ¼ 0.32). Because all 3 of
the common NOD2 CD variants that were genotyped are indepen-
dently associated with CD, we also tested the combined NOD2
genotype (any of the 3 risk alleles) for association, but none was
observed for either of the OFG subphenotypes or for all OFG.
Sequencing of all the coding regions of the NOD2 gene
identiﬁed 15 missense variants (Table 2), 10 of which were rare
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(#0.1%) and occurred in only 1 or 2 individuals. A total of 7
rare variants were considered to be potentially pathogenic
because they were predicted to be damaging/disease causing
by the consensus of the online pathogenicity prediction tools
(Materials and Methods); these were p.A181G, p.S431L,
p.A616E, p.V793M, p.G908C, p.A976T, and p.L1018F.
These included 2 rare variants previously identiﬁed as associ-
ated with risk of CD (p.S431L and p.V793M14), 1 rare variant,
p.G908C, which results in a different amino acid substitution
at a previously known CD-causing variant (p.G908R), and 1
novel variant p.A616E. Excluding p.S431L and p.V793M, the
remaining 5 potentially pathogenic variants have not previ-
ously been implicated in CD etiology nor reported in any of
the large sequencing studies of NOD2 that have been per-
formed in large CD cohorts.9,13,14,37 The novel variant,
p.A616E, identiﬁed in an OFG-only individual has no entry
in the Exome Aggregation Consortium database40—which
contains exome sequencing data from .60,000 individuals—
and is located in the NACHT domain of NOD2. The 4 other
rare deleterious variants were identiﬁed in one OFG-only indi-
vidual (p.G908C) and 4 individuals with OFG+CD (p.A181G,
p.A976T, and p.L1018F). These 4 have been reported in the
Exome Aggregation Consortium database40 but at extremely
low frequency; p.A181G ¼ 0.003%, p.G908C ¼ 0.03%,
p.A976T ¼ 0.02%, and p.L1018F ¼ 0.003% compared with
our observed frequency in OFG which was 10- to 100-fold
greater (Table 2). Three of these variants (p.G908C,
p.A976T, and p.L1018F) are in the leucine-rich repeat domain
of NOD2, which also harbors the 3 common CD-risk variants
(p.R702W, p.G908R, and p.L1007insC), whereas the other 2
are located in the CARD2 domain (p.A181G) and NACHT
domain (p.A616E).
We observed all 3 of the common CD-risk variants in
both OFG subgroups: p.R702W (OFG only ¼ 6/111; OFG
+CD ¼ 9/90), p.G908R (OFG only ¼ 1/111; OFG+CD ¼
4/90), and p.L1007insC (OFG only ¼ 4/111; OFG+CD ¼
8/90) (Table 3). Overall, there was a signiﬁcant difference in
the cumulative frequency of NOD2 variation (P ¼ 0.008) at
these 3 loci between OFG-only patients (11/111, 9.9%) and
patients with OFG+CD (21/90, 23.3%). If we also consider the
7 rare and potentially pathogenic NOD2 variants, then these
cumulative frequencies increase to 13.5% (15/111) of the
OFG-only patients and 27.7% (25/90) of the patients with
OFG+CD, but the difference remains signiﬁcant (P ¼
0.009). The remaining 2 common missense variants detected
by NOD2 sequencing in OFG were known polymorphisms and
considered by pathogenicity prediction tools to be benign or
tolerated and have no functional consequences (p.P268S and
p.V955I).
The sarcoidosis risk variant BTNL2 c.1078G.A
(rs2076530) was associated with disease in all OFG cases
(P ¼ 0.013; OR ¼ 1.33; 95% CI, 1.06–1.67) and had a similar
OR (1.56) and the same direction of effect as seen in sarcoid-
osis.27 However, no association was seen for the subpheno-
types of OFG only or OFG+CD. There was no association of
the atopy risk variants in the FLG gene with OFG for the
individual variants or for the combined analysis of both
variants.
TABLE 1. Association Analysis of 9 Risk Variants from 6 Candidate Genes in 201 OFG Cases, i.e., 90 OFG with
Crohn’s Disease (OFG+CD), 111 OFG Only, and 1023 Population Controls
Gene Variant Allele
Previous Disease
Association
Allele Frequency P for Association
Controls OFG
OFG
+CD
All
OFG P(OFG)
P(OFG/
CD)
P(all
OFG)
IL23R R381Q (rs11209026) A CD and UCa 0.064 0.044 0.022 0.034 0.320 0.038 0.031
NOD2 R702W (rs2066844) A CD 0.055 0.035 0.056 0.044 0.230 1.000 0.440
G908R (rs2066845) C CD 0.011 0.004 0.022 0.012 0.580 0.310 0.980
L1007insC (rs5743293) ins C CD 0.017 0.018 0.044 0.030 1.000 0.023 0.140
Combined Any risk allele CD 0.083 0.058 0.122 0.086 0.260 0.098 1.000
IRGM rs13361189 C CD 0.073 0.081 0.085 0.083 0.753 0.647 0.537
ATG16L1 T300A (rs2241880) G CD 0.487 0.496 0.483 0.502 0.851 0.99 0.939
BTNL2 c.1078A.G (rs2076530) A Sarcoidosis and UC 0.547 0.614 0.619 0.616 0.069 0.076 0.013
FLG R501X STOP(T) AE and Asthma 0.031 0.014 0.023 0.018 0.229 0.726 0.221
2282del4 del(CAGT) AE and Asthma 0.023 0.032 0.017 0.025 0.604 0.798 0.97
Combined Any null allele AE and Asthma 0.054 0.045 0.040 0.043 0.704 0.527 0.44
All variants are known to be strongly associated with Crohn’s disease, ulcerative colitis (UC), sarcoidosis, atopic eczema (AE), or asthma. NOD2 and FLG also include the combined
analysis for all risk alleles tested in these Genes.
aIL23R rs11209026 A allele is protective in both CD and UC.
UC, ulcerative colitis; AE, atopic eczema.
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DISCUSSION
The aim of this study was to begin to address the paucity in
knowledge of the potential genetic basis of OFG. We analyzed
a panel of genetic markers known to be associated with an
increased risk of clinical phenotypes, which overlap with OFG.
Although this is a rare disorder, our case–control study had rea-
sonable power to detect association for most variants tested based
on their reported effect sizes in CD, sarcoidosis, and atopy, espe-
cially if they were reasonably common and/or had a higher risk
for disease. Power varied from 67% to 100% at the deﬁned alpha-
level (a ¼ 0.05) in the whole OFG group, except for the CD-risk
variant at IRGM (40%) and the AD risk variant p.R501X at FLG
gene (43%). However, power in the smaller OFG-only group was
lower, with a range of 30%–99% for all variants tested. Genetic
effect sizes in common complex disorders are generally low and
will therefore be very difﬁcult to detect in a rare disease, such as
OFG. However, it is possible that the variants that predispose to
this condition are themselves rare, with larger effects sizes, which
would make the detection of such effects in smaller sample sizes
achievable.
The combined analysis of the 3 common NOD2 CD-risk
variants showed no association with either OFG alone, OFG+CD,
or all OFG, despite being well powered to do so (power . 99%).
This suggests that NOD2 does not make a substantial contribution
to OFG risk. However, there was evidence of association of the p.
L1007insC variant in the OFG+CD group, and the association
showed a similar OR of 2.67 (95% CI, 1.22–5.85) and direction
of effect to CD. This was also the case for IL23R p.R381Q, which
was associated in the OFG+CD group with an OR of 0.34
(0.12–0.92), showing a similar protective effect to that seen in
CD. The other 2 CD-risk loci examined, ATG16L1 and IRGM, did
not show any association with subgroups or with all OFG
TABLE 2. All NOD2 Variants Detected by Sanger Sequencing of 201 OFG Cases
Exon Missense Variant dbSNP Identiﬁer
Frequency (%) Consensus Pathogenicity
PredictionAll OFG Controls
1 p.A8S rs764563350 0.29 ,0.01 NEUTRAL
3 p.A181G rs141414002 0.29 0.003 DELETERIOUS
4 p.P268S rs2066842 30.36 34 NEUTRAL
4 p.S431L rs104895431 0.56 0.1 DELETERIOUS
4 p.A616E NOVEL c.1952C.A 0.27 Unknown DELETERIOUS
4 p.R702W rs2066844 5.19 2 DELETERIOUS
4 p.C706S rs539297110 0.28 ,0.01 NEUTRAL
4 p.R713H rs104895483 0.28 ,0.01 NEUTRAL
4 p.V793M rs104895444 0.28 0.1 DELETERIOUS
8 p.G908C rs2066845[G.T] 0.28 0.0345 DELETERIOUS
8 p.G908R rs2066845[G.C] 1.69 1 DELETERIOUS
9 p.V955I rs5743291 8.11 6 NEUTRAL
10 p.A976T rs148561632 0.52 ,0.01 DELETERIOUS
11 p.L1007insC rs2066847 3.01 1.3 DELETERIOUS
12 p.L1018F rs146435555 0.27 ,0.01 DELETERIOUS
Bold variants are known Crohn’s disease risk variants. The frequency of the variant allele as determined by sequencing data in OFG patients is given along with control frequencies
according to either the National Centre for Biotechnology Information (NCBI) single Nucleotide Polymorphism Database (dbSNP) or the Exome Aggregation Consortium (ExAC)
datatbase.
TABLE 3. The Number of Occurrences of Each of the
Rare and Common Pathogenic NOD2 Missense Variants
in OFG-Only Patients (OFG, n ¼ 111) or OFG Patients
with Concurrent Crohn’s Disease (OFG+CD, n ¼ 90)
Variant
No. Individuals
OFG Only OFG+CD
Rare A181G 1
S431La 1
A616E 1
V793Ma 1
G908C 1
A976T 2
L1018F 1
Common R702W 6b 9c
G908R 1 4
L1007insC 4 8
TOTAL 15 (13.5%) 25 (27.7%)
aRivas et al variants.13
bIncludes 2 homozygous individuals.
cIncludes one homozygous individual.
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although this could have been a result of the reduced power at
these loci. Thus, evidence of association of CD-risk variants with
disease in this study was restricted to subgroups that included
patients with intestinal inﬂammation (CD+OFG or all OFG). This
ﬁnding could be explained by insufﬁcient power to detect asso-
ciation in the OFG-only group (discussed above) or that OFG
only is a genetically distinguishable disease entity, a view that
is consistent with our previous clinically based observations
(Campbell et al, 2011).
The other positive ﬁnding in our study was the association
of the variant rs2076530 in BTNL2 with OFG in our full panel of
OFG cases but not in either of the subphenotype categories (with
or without intestinal CD). This variant has been associated with
susceptibility to adult-onset sarcoidosis in multiple studies.26,27
Sarcoidosis and CD have been found to occur together in fami-
lies.41,42 This led to the suggestion of an overlapping genetic
etiology for these 2 disorders, which is supported by our results.
The risk allele causes formation of a truncated gene product which
displays abnormal cellular localization.27
The BTNL2 protein is proposed to function as a costimu-
latory molecule for T cells under physiological conditions.
BTNL2 negatively regulates T-cell activation independently of
CD28 and CTLA-4 is predominantly expressed in gastrointesti-
nal tissues and is overexpressed in mouse models of colitis.43
Recently, it has been shown that BTNL2 promotes the expression
of Foxp3, a transcription factor required for regulatory T-cell
development and function.44 Thus, mutations in BTNL2 may
affect its ability to regulate T-cell activation in response to muco-
sal inﬂammation. We recently reported the association of a rare
variant in BTNL2 with CD and ulcerative colitis.30 The rare mis-
sense variant (p.G454C) is not in linkage disequilibrium with the
common splicing variant, and is thus likely to be an independent
effect, but further supports a potential role for BTNL2 in these
related disorders. However, BTNL2 is located on chromosome
6p21 very close to the human MHC class II region. This complex
region of the genome exhibits extensive linkage disequilibrium,
and therefore it is important to establish independence of the
association of the BTNL2 risk allele from nearby MHC class II
genes. This will require additional ﬁne mapping studies that
target this region.
An important question arising from the genetic data is
whether the lack of association of the 3 common NOD2 risk
variants in the OFG-only group (Table 1) implies a real difference
in the underlying pathogenesis of OFG and CD. Although the
sample size of OFG-only cases was small (N ¼ 111), we had
high power to detect the large effect sizes for NOD2 risk variants
in this subgroup (.90%), which suggests either that NOD2 does
not contribute to the development of OFG or that the effect sizes
are much smaller for these variants than in CD. An alternative
analysis to address this question was used by Gale et al,15 who
compared the proportion of cases in the OFG-only group with that
in the CD+OFG group that carried any of the 3 common NOD2
risk variants, found that although 4 of 12 patients with OFG+CD
carried one of these variants, they were absent in all 17 OFG-only
patients. We compared 111 patients with OFG with 90 patients
with OFG+CD and found a signiﬁcantly lower frequency of com-
mon NOD2 mutations in the OFG-only group versus OFG+CD
(10% versus 23%, P ¼ 0.008), which is broadly consistent with
the data of Gale et al. However, our NOD2 sequencing data,
which identiﬁed 3 rare and likely pathogenic NOD2 variants in
4 of 90 cases in the OFG+CD cohort (p.A181G, p.A976T, and
p.L1018F) and 4 rare and likely pathogenic NOD2 variants in 4 of
111 OFG-only patients (p.S431L, p.A616E, p.V793M, and
p.G908C), suggest that rare NOD2 variants might play a role in
OFG only. Nevertheless, inclusion of all 7 rare and potentially
pathogenic variants along with the 3 common CD-risk variants in
a combined analysis of all NOD2 risk alleles results in a lower
cumulative risk allele frequency of 7.7% in the OFG-only group
compared with 14.4% in the OFG+CD group (P ¼ 0.04). This
suggests that NOD2 may be an important factor in distinguishing
OFG+CD from OFG only.
It has repeatedly been reported that patients with CD and
NOD2 variants are more likely to have the ileal form of the
disease and develop ﬁbrostenosis requiring surgical resection,45,46
but any association with oral involvement has not been previously
described. There is evidence that the NOD2 p.L1007insC variant
associated with OFG+CD in this study, in addition to the 2 other
major CD-risk variants occurring in NOD2, results in a failure of
the appropriate primary immune response to bacterial components
such as muramyl dipeptide, and attenuated activation of the
ATG16L1 autophagy pathway,47 or alternatively may result in
a gain-of-function downregulating the normally inhibitory cyto-
kine, Il-10.48 The true mechanism remains unclear, but neverthe-
less, the end result is chronic inﬂammation of the intestinal tract in
individuals with CD. Our results suggest that missense coding
variation in NOD2 in patients with OFG may reﬂect the presence
of intestinal disease.
The observation that NOD2 is associated with the develop-
ment of OFG+CD but not OFG only in this study supports the
possibility that these disorders may be genetically distinguishable
once a systematic investigation of genetic risk factors in OFG has
been performed. The ﬁnding of substantial differences in the
genetic architecture of OFG could have signiﬁcant diagnostic
and therapeutic implications because patients with OFG may be
best treated with therapy different from that used for CD. For
example, there is good evidence that patients with OFG respond
to diets excluding cinnamon and benzoates,3,49 whereas the pres-
ence of CD in conjunction with OFG predicts a response to a typ-
ical CD therapy.50,51
Overall, these observations regarding the genetics of
OFG suggest that OFG and CD are relatively distinct disease
entities. Nonetheless, a genetic contribution to the pathogen-
esis of OFG remains highly plausible as is the case for most
chronic inﬂammatory conditions. A logical next step in the
work presented here would be to expand the cohort of well-
characterized patients with OFG to the point where a well-
powered genome-wide association study could be performed
to better deﬁne the genetics of OFG.
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